ID: MRFR/Pharma/3411-HCR | 85 Pages | Published By Rahul Gotadki on March 2023
 Figure 1- Market Synopsis of the Global Paraganglioma Market Research, by Region, 2016 (%)
Sources- WHO, cancer research UK, American Cancer Society
Segmentation
The global paraganglioma market is segmented on the basis of types, treatment, and end users.
On the basis of types, the market is segmented into caroid paraganglioma, cervical paraganglioma, jugular paraganglioma, secretory paraganglioma, temporal paraganglioma, vagal paraganglioma, and others.
On the basis of the treatment, the market is categorized into therapeutic treatment and diagnostic treatment. The therapeutic treatment is further segmented into surgery, embolization, and radiotherapy. The embolization is further categorized into liquid embolic agents, sclerosing agents, particulate embolic agents, and others. The radiotherapy is sub-segmented into external beam radiation therapy, brachytherapy, and unsealed source radiotherapy. The diagnostic treatments are further segmented into CT scans, MRI, angiography, blood test, and others.
On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Â
Regional Analysis
The Americas account for the major share of the global paraganglioma market owing to the increasing prevalence of paragangliomas, well-developed technology and increasing government support for research & development. Moreover, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas paraganglioma market. The concentration of major players in this region is likely to support the growth of the market during the forecasted period.
Europe holds the second largest paraganglioma market, which is followed by Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. Asia Pacific is the fastest growing paraganglioma market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa and limited availability of funds and availability of medical facilities. The Middle East dominates the Middle East & Africa Paraganglioma market due to the presence of well-developed countries like Kuwait, Qatar, Oman and South Arabia. Whereas, Africa region is expecting a healthy growth due to the presence of huge opportunity for the development of the market.
Market Assessment
Sources- WHO, cancer research UK, American Cancer Society
Â
Key Players in Global Paraganglioma Market
Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Â Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.).
Intended Audience
Â
Report Attribute/Metric | Details |
---|---|
Market Size | USD 3,264 Million |
CAGR | 2022-2030: 1.00% |
Base Year | 2021 |
Forecast Period | 2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Types, treatment, and end users |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.) |
Key Market Opportunities |
|
Key Market Drivers | Increasing number of patients suffering from paragangliomas and continuous advances in the treatment |
paraganglioma market CAGR would be 1.00% during the forecast period.
paraganglioma market restraint would be its high cost of treatment.
The Americas would take the lead of the paraganglioma market.
The Asia Pacific paraganglioma market would be the fastest-growing one.
The treatment types included in the paraganglioma market report are therapeutic treatment and diagnostic treatment.